Lipophilicity can be measured with different methods, such as Shake-Flask or liquid chromatography. HPLC presents the advantage of overcoming solubility issues and therefore extending the range of lipophilicity to high values. A specific HPLC method, called ELogD, had been developed 20 years ago on a C16-amide stationary phase, enhancing hydrophobic and hydrogen bond interactions to mimic octanol-water partition. The emergence of novel stationary phases and the need for a less complex mobile phase have led to the development of a new HPLC assay called alphaLogD, applicable to neutral and basic compounds at pH 7.4, that combines superficially porous particles with a high number of equilibriums between solutes and stationary phase, leading to a lower number of isocratic methods to determine the logk'w at a higher throughput. Statistical studies have been run to successfully evaluate the alphaLogD method compared to the Shake-Flask method and to allow this lipophilicity measurement into the so-called Beyond-Rule-of-5-molecules space.
22 December 2025 in Journal of Medicinal Chemistry
Cyclic peptides are a promising class of therapeutics that have the potential for oral bioavailability but are hindered by cell membrane permeability and aqueous solubility. Artificial intelligence (AI) can address the challenging multiparameter optimization of cyclic peptides, but it relies on wet lab ground truth biological data that are scarce, sparse, and dominated by hydrophobic amino acids. Here, we introduce PEGASUS, a multimodal AI model that achieves state-of-the-art performance in predicting cell membrane permeability. PEGASUS integrates an innovative high-throughput proxy biological assay (1910 PPA), which generates billions of cyclic peptides separated by permeability-related characteristics with solvent-dependent computational simulations. PEGASUS informs rules for designing cell-permeable cyclic peptides with high aqueous solubility that resemble FDA-approved therapeutics based on polarity and charge. Combining these rules with a novel generative AI, we design the first published cyclic peptides with more than two polar or ionizable fragments to achieve in vitro cell membrane permeability.